

## Supplemental Data

### The Vam6 GEF Controls TORC1 by Activating the EGO Complex


Matteo Binda, Marie-Pierre Péli-Gulli, Grégory Bonfils, Nicolas Panchaud, Jörg Urban, Thomas W. Sturgill, Robbie Loewith, and Claudio De Virgilio

**Table S1. Strains Used in This Study**

Strain	Genotype	Source	Figure
BY4741	<i>MATa; his3Δ1, leu2Δ0, ura3Δ0, met15Δ0</i>	Euroscarf	
BY4742	<i>MATα; his3Δ1, leu2Δ0, ura3Δ0, lys2Δ0</i>	Euroscarf	3C
YL515	[BY4741/2] <i>MATα; his3Δ1, leu2Δ0, ura3Δ0</i>	This study	1A, B, D; 2; 3B; 4A, B; 5A, E, G-K ; 6B-D; S1; S2
YL516	[BY4741/2] <i>MATa; his3Δ1, leu2Δ0, ura3Δ0</i>	This study	3C, D; 5B-D, F; 6A
MB25	[YL515] <i>MATα; ego1Δ::HIS3</i>	This study	1A
MB26	[YL515] <i>MATα; ego3Δ::HIS3</i>	This study	1A
MB27	[YL515] <i>MATα; gtr1Δ::HIS3</i>	This study	1A, D; 2A
MB28	[YL515] <i>MATα; gtr2Δ::HIS3</i>	This study	1A; 2A
MB34	[YL515] <i>MATα; tco89Δ::HIS3</i>	This study	1A, D
MB32	[YL516] <i>MATa; gtr1Δ::kanMX4</i>	This study	1C; 3D; 5A-D; S1, 3
MB33	[YL516] <i>MATa; gtr2Δ::kanMX4</i>	This study	2B; 5B, C; S1
YJU531	[YL516] <i>MATa; tco89Δ::natMX</i>	This study	5D
MP07-1D	[YL516] <i>MATa; vam6Δ::kanMX4</i>	This study	5A-C, F, K; 6A, C, D
MP02-7B	[YL515] <i>MATα; gtr1Δ::kanMX4, tco89Δ::HIS3</i>	This study	1B, C
MP06-8B	[YL515] <i>MATα; gtr1Δ::kanMX4, gtr2Δ::kanMX4</i>	This study	3A
MB35	[YL515] <i>MATα; gln3Δ::HYGR</i>	This study	S1
MB36-2C	[YL516] <i>MATa; gtr1Δ::kanMX4, gln3Δ::HYGR</i>	This study	S1
MP01-4D	[YL516] <i>MATa; gtr2Δ::kanMX4, gln3Δ::HYGR</i>	This study	S1
YJU537	[YL516] <i>MATa; EGO1-GFP::kanMX6</i>	This study	6A, B
MP56	[YL516] <i>MATa; TCO89-GFP::kanMX6</i>	This study	6A, B
KT1960	<i>MATa; his3, leu2, ura3, trp1</i>	<sup>1</sup>	
FD34	[KT1960] <i>MATa; his3, leu2, ura3, trp1, KOG1-TAP::HIS3</i>	This study	4B, E
FD35	[KT1960] <i>MATa; his3, leu2, ura3, trp1, TCO89-TAP::HIS3</i>	This study	4A, D
MP52-2A	[YL516] <i>MATa; TOR1-D330-3xGFP</i>	This study	6A, B
Y07050	[BY4741] <i>MATa; gap1Δ::kanMX4</i>	Euroscarf	2C, D
Y00575	[BY4741] <i>MATa; ypt7Δ::kanMX4</i>	Euroscarf	5A, K; 6C, D
MB56	[BY4741] <i>MATa; GTR1-GFP::HIS3</i>	<sup>2</sup>	6A
NMY51	<i>MATa; his3Δ200, trp1-901, leu2-3,112, ade2, LYS2::(lexAop)4-HIS3, ura3::(lexAop)8- lacZ, ade2::(lexAop)8-ADE2, GAL4</i>	Dual-systems Biotech AG	4C

**Table S2. Plasmids Used in This Study**


Plasmid	Description	Source	Figure
pRS413	CEN, <i>HIS3</i>	<sup>3</sup>	1; 2A, B; 3B, C; 5B-E; 6A, C; S1
pRS415	CEN, <i>LEU2</i>	<sup>3</sup>	1; 2; 3A-C; 5B-D; 6B-D; S1-3
pRS416	CEN, <i>URA3</i>	<sup>3</sup>	1D; 2B-D; 3A, B; 5B; 6; S2
YCplac33	CEN, <i>URA3</i>	<sup>4</sup>	1C; 3D
pJU660	[pRS415] <i>GTR1</i>	This study	1B; 3A
pJU656	[pRS415] <i>GTR1</i> <sup>S20L</sup>	This study	1B; 3A
pMB1483	[pRS415] <i>GTR1</i> <sup>Q65L</sup>	This study	1B; 3A
pJU651	[pRS416] <i>GTR2</i>	This study	3A
pJU654	[pRS416] <i>GTR2</i> <sup>S23L</sup>	This study	3A
pJU655	[pRS416] <i>GTR2</i> <sup>Q66L</sup>	This study	3A
pMB1393	[YCplac33] <i>Tet<sub>ON</sub>-GTR1</i>	This study	1C; 3D; S3
pMB1394	[YCplac33] <i>Tet<sub>ON</sub>-GTR1</i> <sup>Q65L</sup>	This study	1C; 3D; S3
pMB1395	[YCplac33] <i>Tet<sub>ON</sub>-GTR1</i> <sup>S20L</sup>	This study	1C; 3D
pMB1344	[YCplac33] <i>GTR1-TAP</i>	This study	5I, K
pMB1371	[YCplac33] <i>GTR1</i> <sup>S20L</sup> - <i>TAP</i>	This study	5I
pMB1372	[YCplac33] <i>GTR1</i> <sup>Q65L</sup> - <i>TAP</i>	This study	5I
YCpIF2	CEN, <i>LEU2</i> , <i>GAL1-GST</i>	<sup>5</sup>	
pMB1348	[YCpIF2] <i>GAL1-GST-GTR1</i>	This study	4A, B,
pMB1579	[YCpIF2] <i>GAL1-GST-GTR1</i> <sup>Q65L</sup>	This study	4A, B
pMB1580	[YCpIF2] <i>GAL1-GST-GTR1</i> <sup>S20L</sup>	This study	4A, B
pMB1667	[YCpIF2] <i>GAL1-GST-GTR1</i> , <i>leu2::URA3</i>	This study	4D, E
pMB1668	[YCpIF2] <i>GAL1-GST-GTR1</i> <sup>Q65L</sup> , <i>leu2::URA3</i>	This study	4D, E
pVW1146	[YIpIF2] <i>GAL1-GTR1</i>	This study	5A, E
pVW1148	[YIpIF2] <i>GAL1-GTR1</i> <sup>S20L</sup>	This study	5A, E
pJU1064	[pRS413] <i>SCH9</i> <sup>T570A</sup> - <i>HA<sub>3</sub></i>	<sup>6</sup>	2C, D; 3D; 6D; S2; S3
pJU1030	[pRS416] <i>SCH9</i> <sup>T570A</sup> - <i>HA<sub>3</sub></i>	<sup>6</sup>	1A,B; 3C; 5C; S1
pCDV1084	[YCpIF2] <i>ADH1-GST-EGO1</i>	<sup>7</sup>	5I, K
pMPG1574	2μ, <i>Tet<sub>ON</sub>-HIS<sub>6</sub>-HA<sub>3</sub></i> , <i>URA3</i>	This study	5D, E, H
pMPG1576	[pMPG1574] <i>Tet<sub>ON</sub>-HIS<sub>6</sub>-HA<sub>3</sub>-VAM6</i>	This study	5D, E, G, H
pPL132	[pRS315] <i>HA<sub>3</sub>-TOR1</i>	<sup>8</sup>	1D; 5F
pPL155	[pRS315] <i>HA<sub>3</sub>-TOR1</i> <sup>A1957V</sup>	<sup>8</sup>	1D; 5F
pPL156	[pRS315] <i>HA<sub>3</sub>-TOR1</i> <sup>I1954V</sup>	<sup>8</sup>	1D; 5F
pPL157	[pRS315] <i>HA<sub>3</sub>-TOR1</i> <sup>W2176R</sup>	<sup>8</sup>	1D
pMB1650	[pGEX3X] <i>RAS2</i>	This study	5G, H
pMB1651	[pGEX3X] <i>YPT7</i>	This study	5G, H
pJU1032	[pGEX6P] <i>GTR1-HIS<sub>6</sub></i>	This study	5G, H
pJU1015	[pET28a] <i>GTR2</i>	This study	5G
pJU793	[pRS416] <i>GFP-SCH9</i>	<sup>6</sup>	6A
pJOD10	CEN, <i>URA3</i> , <i>GAL1-GAP1-GFP</i>	<sup>9</sup>	2A
pMB1730	[pRS413] <i>ADH1-RFP-VAM6</i>	This study	6B
pMB1379	[YCplac33] <i>MET15</i>	This study	2C, D; 6C, D
pMPG1728	[pRS413] <i>CYC1-GFP-VAM6</i>	This study	6A
pDL2-Alg5	2μ, <i>ADH1-HA-NUBG</i> , <i>TRP1</i>	Dualsystems	4C
pCabWT	CEN, <i>CYC1-CUB-LEXA</i> , <i>LEU2</i>	Dualsystems	4C
pNP1711	[pCabWT] <i>CYC1-TCO89-CUB-LEXA</i>	This study	4C
pNP1712	[pCabWT] <i>CYC1-EGO1-CUB-LEXA</i>	This study	4C
pPR3-N	2μ, <i>CYC1-NUBG-HA</i> , <i>TRP1</i>	Dualsystems	
pNP1689	[pPR3-N] <i>CYC1-NUBG-HA-GTR1</i>	This study	4C
pNP1690	[pPR3-N] <i>CYC1-NUBG-HA-GTR1</i> <sup>Q65L</sup>	This study	4C
pNP1691	[pPR3-N] <i>CYC1-NUBG-HA-GTR1</i> <sup>S20L</sup>	This study	4C



**Figure S1. Loss of the TORC1 Downstream Effector Gln3 Suppresses the Defect in Recovery following Rapamycin Treatment, but Not the TORC1 Activity Defect, of EGO Complex Mutants**


(A) Indicated strains were assayed (as in Figure 1A) for their ability to recover from a rapamycin treatment.

(B) TORC1 activity was assayed in exponentially growing wild-type, *gln3Δ*, *gtr1Δ*, *gtr2Δ*, *gtr1Δ gln3Δ*, and *gtr2Δ gln3Δ* strains, which were treated, or not, with the indicated drugs as in Figure 1A.



**Figure S2. TORC1 Activation following Cycloheximide Treatment Does Not Depend on Uptake of Extracellular Amino Acids**

Prototroph wild-type cells were either grown on YPD (+ 0.2% glutamine) or on SD (75 mM  $\text{NH}_4^+$ ; without amino acids) and analysed for TORC1 activity prior to (EXP) and following a 30-min cycloheximide (CHX) treatment. For details see Figure 1A.



**Figure S3. TORC1 Inactivation following  $\text{NH}_4^+$  Starvation Is Not Reversed by Overproduction of Gtr1<sup>GTP</sup>**

Prototroph *gtr1Δ* cells carrying either a vector that expresses *GTR1* or *GTR1<sup>GTP</sup>* from the doxycycline-inducible (*Tet<sub>ON</sub>*) promoter were grown exponentially on  $\text{NH}_4^+$ -rich medium (EXP), transferred to  $\text{NH}_4^+$ -free medium (at time point 0), and assayed for TORC1 activity (as in Figure 2C) at the times indicated.

## References

1. Pedruzzi, I. *et al. Mol. Cell* **12**, 1607-1613 (2003).
2. Huh, W. K. *et al. Nature* **425**, 686-691 (2003).
3. Brachmann, C. B. *et al. Yeast* **14**, 115-132 (1998).
4. Gietz, R. D. & Sugino, A. *Gene* **74**, 527-534 (1988).
5. Foreman, P. K. & Davis, R. W. *Gene* **144**, 63-68 (1994).
6. Urban, J. *et al. Mol. Cell* **26**, 663-674 (2007).
7. Dubouloz, F., Deloche, O., Wanke, V., Cameroni, E. & De Virgilio, C. *Mol. Cell* **19**, 15-26 (2005).
8. Reinke, A., Chen, J. C., Aronova, S. & Powers, T. *J. Biol. Chem.* **281**, 31616-31626 (2006).
9. Nikko, E., Marini, A. M. & André, B. *J. Biol. Chem.* **278**, 50732-50743 (2003).